Term
|
Definition
| Inactivation moves Stem cells to Aberrant crypt cell |
|
|
Term
|
Definition
| Activation moves Stem cells to Aberrant crypt cell |
|
|
Term
|
Definition
| Activation moves Aberrant crypt cell to Early Adenoma |
|
|
Term
|
Definition
| Inactivation moves Early Adenoma to Late Adenoma |
|
|
Term
|
Definition
| Inactivation moves Late Adenoma to Carcinoma |
|
|
Term
|
Definition
| Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the extracellular domain of the HER2 protein, which is overexpressed in 25 to 30% of primary breast cancers. By binding to the HER2 protein, trastuzumab inhibits the growth of tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) in cancer cells that overexpress the HER2 protein |
|
|
Term
| kinase inhibitors type I inhibitors |
|
Definition
| arget the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated |
|
|
Term
| kinase inhibitors type II inhibitors |
|
Definition
| have revealed a new binding mode that exploits an additional binding site immediately adjacent to the region occupied by ATP. This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation |
|
|
Term
| kinase inhibitors type III inhibitors |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Angiogenesis in Cancer Therapy |
|
Definition
Monoclonal antibody: Bevacizumab (Anti-VEGF-A)
● Small molecule: TKIs
(Sunitinib, Sorafenib, AG013736, ZD6474 etc.) |
|
|
